Aavogen is a biotechnology company dedicated to pioneering and developing novel adeno-associated virus (AAV) based gene therapies for a range of serious genetic and acquired diseases. The company leverages proprietary capsid engineering technologies and innovative vector designs to enhance the safety, efficacy, and deliverability of gene therapies. Aavogen's primary focus is on addressing unmet medical needs by translating cutting-edge scientific discoveries into potentially life-changing treatments for patients worldwide. Their research pipeline includes programs targeting rare diseases as well as more common conditions where gene therapy holds significant promise.
The headquarters serves as the central hub for Aavogen's research and development activities, corporate strategy, business development, and administrative operations.
The facility likely includes state-of-the-art laboratories for AAV vector design, molecular biology, cell culture, and preclinical research, designed to foster innovation and collaboration.
The work culture at Aavogen's headquarters is expected to be highly collaborative, science-driven, and fast-paced, with a strong emphasis on innovation, scientific rigor, and a patient-centric mission. Employees likely share a passion for advancing gene therapy.
Locating in South San Francisco provides Aavogen with access to a rich ecosystem of leading academic institutions, experienced biotech talent, venture capital, and potential collaborators, crucial for a company in the gene therapy space.
While Aavogen's primary physical operations are concentrated in the United States (South San Francisco, CA and potentially Gaithersburg, MD), its impact and collaborations are global. The company engages with international research institutions, partners with contract manufacturing organizations (CMOs) and contract research organizations (CROs) globally for its development programs, and aims to serve patients worldwide with its future therapies. Clinical trials, as they advance, will likely involve sites in multiple countries.
250 E Grand Ave, Suite 70
South San Francisco
CA
USA
Address: 2 W dislocations, Gaithersburg, MD 20878, USA (Note: Address search points to this general area based on some directory listings, specific suite unknown)
To facilitate engagement with East Coast research institutions, contract research organizations (CROs), and regulatory bodies, expanding Aavogen's operational footprint and access to specialized talent.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, AAVogen' leadership includes:
AAVogen has been backed by several prominent investors over the years, including:
Information on executive hires or exits in the last 12 months is not readily available in public sources. Private companies like Aavogen often do not publicly announce all executive changes unless they are of major significance or part of a funding/IPO announcement.
Discover the tools AAVogen uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Based on common biotech industry patterns and available contact information, Aavogen likely uses email formats such as [first_initial][last]@aavogen.com or [first].[last]@aavogen.com.
[first_initial][last]@aavogen.com
Format
chodgson@aavogen.com
Example
80%
Success rate
PR Newswire • September 1, 2021
Aavogen, Inc. presented data at the 21st Annual Meeting of the Angiogenesis, Exudation, and Degeneration 2021 virtual conference, showcasing promising results for its AVG-001A gene therapy candidate in treating wet age-related macular degeneration (AMD) in non-human primates....more
PR Newswire • January 7, 2020
Aavogen, Inc. announced a research collaboration with Massachusetts Eye and Ear to develop a novel gene therapy for dry age-related macular degeneration (AMD), leveraging Aavogen's proprietary AAV technology platform....more
Foundation Fighting Blindness • July 13, 2023
The Foundation Fighting Blindness, through its Retinal Degeneration Fund, has invested $1 million in Aavogen to support the preclinical development of a novel AAV gene therapy for Stargardt disease, the most common form of inherited macular degeneration....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including AAVogen, are just a search away.